Anika Therapeutics (NASDAQ:ANIK) updated its FY 2021 earnings guidance on Tuesday. The company provided EPS guidance of $- for the period. The company issued revenue guidance of $143.50 million-147.42 million, compared to the consensus revenue estimate of $144.15 million.
Separately, Zacks Investment Research raised shares of Anika Therapeutics from a sell rating to a hold rating in a report on Thursday, May 6th.
Shares of ANIK stock traded down $1.07 on Friday, reaching $43.69. The stock had a trading volume of 2,557 shares, compared to its average volume of 129,933. The stock’s 50-day moving average price is $42.54. The stock has a market capitalization of $628.74 million, a price-to-earnings ratio of -23.68, a price-to-earnings-growth ratio of 24.26 and a beta of 1.21. Anika Therapeutics has a 12 month low of $31.55 and a 12 month high of $48.37.
In other Anika Therapeutics news, Director Raymond J. Land sold 2,000 shares of the stock in a transaction that occurred on Wednesday, May 12th. The shares were sold at an average price of $42.60, for a total transaction of $85,200.00. Following the transaction, the director now owns 7,953 shares in the company, valued at approximately $338,797.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.09% of the stock is currently owned by corporate insiders.
About Anika Therapeutics
Anika Therapeutics, Inc, together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses.
Further Reading: Bollinger Bands
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.